Citalopram to treat depression in pediatric oncology

Margaret DeJong; Eric Fombonne

doi:10.1089/cap.2006.0076

Citalopram to treat depression in pediatric oncology

Margaret DeJong, Eric Fombonne

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

Original language	English (US)
Pages (from-to)	371-377
Number of pages	7
Journal	Journal of Child and Adolescent Psychopharmacology
Volume	17
Issue number	3
DOIs	https://doi.org/10.1089/cap.2006.0076
State	Published - Jun 2007
Externally published	Yes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1089/cap.2006.0076

Cite this

@article{a720032c116e4a30ba2e42c09e9c9bdb,

title = "Citalopram to treat depression in pediatric oncology",

abstract = "We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.",

author = "Margaret DeJong and Eric Fombonne",

year = "2007",

month = jun,

doi = "10.1089/cap.2006.0076",

language = "English (US)",

volume = "17",

pages = "371--377",

journal = "Journal of Child and Adolescent Psychopharmacology",

issn = "1044-5463",

publisher = "Mary Ann Liebert Inc.",

number = "3",

}

TY - JOUR

T1 - Citalopram to treat depression in pediatric oncology

AU - DeJong, Margaret

AU - Fombonne, Eric

PY - 2007/6

Y1 - 2007/6

N2 - We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

AB - We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

UR - http://www.scopus.com/inward/record.url?scp=34447506372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447506372&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.0076

DO - 10.1089/cap.2006.0076

M3 - Article

C2 - 17630871

AN - SCOPUS:34447506372

SN - 1044-5463

VL - 17

SP - 371

EP - 377

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

IS - 3

ER -

Citalopram to treat depression in pediatric oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this